Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol

Nat Clin Pract Nephrol. 2007 Apr;3(4):227-32. doi: 10.1038/ncpneph0443.

Abstract

Background: A 17-year-old Filipino male hemodialysis patient presented for renal transplant evaluation. He had significant skeletal abnormalities characterized by bone pain, an inability to walk, and secondary hyperparathyroidism despite therapy with an active vitamin D sterol (paricalcitol).

Investigations: The patient underwent a physical examination, and his serum levels of calcium, phosphorus, alkaline phosphatase, parathyroid hormone, aluminum and 25-hydroxycholecalciferol (25OH-vitamin D) were determined. X-rays of hips and lower extremities, MRI, and bone histomorphometry after double tetracycline labeling were performed.

Diagnosis: Osteomalacia associated with low 25OH-vitamin D levels.

Management: Monthly therapy with ergocalciferol (vitamin D2) and discontinuation of paricalcitol.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Bone Density Conservation Agents / adverse effects*
  • Bone Density Conservation Agents / therapeutic use
  • Ergocalciferols / adverse effects
  • Ergocalciferols / blood
  • Ergocalciferols / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Hyperparathyroidism, Secondary / complications
  • Hyperparathyroidism, Secondary / drug therapy*
  • Kidney Failure, Chronic / therapy*
  • Male
  • Osteomalacia / blood
  • Osteomalacia / chemically induced*
  • Renal Dialysis / adverse effects*
  • Vitamin D Deficiency / blood
  • Vitamin D Deficiency / chemically induced

Substances

  • Bone Density Conservation Agents
  • Ergocalciferols
  • paricalcitol